biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > 2-million-dollar fee

<< Previous

Bullboard Posts

Next >>

Comment by ronrydellon Jan 20, 2023 11:21am

126 Views

Post# 35235575

RE:RE:RE:RE:RE:RE:RE:2-million-dollar fee

I agree....we could have $50 ADR's several years down the road if the glioblastoma trials worked and we got FDA approval....For us heavy share Bioasis holders...we would at least get our money back so both Medatech shareholders and Bioasis should vote yes (IMHO) and they hope and wait.

Bioasis will fold shortly staying on it's own, the requested for more debentures to give us warrants is long gone.

<< Previous

Bullboard Posts

Next >>

Covalon Technologies posts third profitable quarter in a row